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Gamma Glutamyltransferase Reduction Is 
Associated With Favorable Outcomes in 
Pediatric Primary Sclerosing Cholangitis
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Adverse clinical events in primary sclerosing cholangitis (PSC) happen too slowly to capture during clinical trials. Surrogate 
endpoints are needed, but no such validated endpoints exist for children with PSC. We evaluated the association between 
gamma glutamyltransferase (GGT) reduction and long-term outcomes in pediatric PSC patients. We evaluated GGT nor-
malization (< 50 IU/L) at 1 year among a multicenter cohort of children with PSC who did or did not receive treatment with 
ursodeoxycholic acid (UDCA). We compared rates of event-free survival (no portal hypertensive or biliary complications, 
cholangiocarcinoma, liver transplantation, or liver-related death) at 5 years. Of the 287 children, mean age of 11.4 years old, 
UDCA was used in 81% at a mean dose of 17 mg/kg/day. Treated and untreated groups had similar GGT at diagnosis (314 
versus 300, P = not significant [NS]). The mean GGT was reduced at 1 year in both groups, with lower values seen in treated 
(versus untreated) patients (99 versus 175, P = 0.002), but 5-year event-free survival was similar (74% versus 77%, P = NS). In 
patients with GGT normalization (versus no normalization) by 1 year, regardless of UDCA treatment status, 5-year event-
free survival was better (91% versus 67%, P < 0.001). Similarly, larger reduction in GGT over 1 year (> 75% versus < 25% 
reduction) was also associated with improved outcome (5-year event-free survival 88% versus 61%, P = 0.005). Conclusion: A 
GGT < 50 and/or GGT reduction of > 75% by 1 year after PSC diagnosis predicts favorable 5-year outcomes in children. 
GGT has promise as a potential surrogate endpoint in future clinical trials for pediatric PSC.  (Hepatology Communications 
2018;2:1369-1378)
Primary sclerosing cholangitis (PSC) is a rare progressive disease of the liver characterized by cholestasis and ongoing destruction of the bile ducts.(1) Compared with adult patients, children with PSC more commonly present with co-occurring autoimmune hepatitis (AIH), have fewer dominant 
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IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid.
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strictures, and have a lower incidence of cholangio-
carcinoma. Long-term outcomes are poor. Within 10 
years of diagnosis, 30% of children will require liver 
transplantation and 50% of children will have devel-
oped complications of biliary stricturing or portal 
hypertension.(2) There is no known effective treatment 
to stop the progression of biliary and liver fibrosis.(3) 
PSC is recognized as having one the largest unmet 
needs in hepatology.(4)
The slow progression of PSC hinders attempts at 
pharmaceutical trials. With only 5% of children expe-
riencing an adverse clinical outcome event annually,(2) 
most patients will not reach clinical endpoints during 
the timeframe of a clinical trial. Adequate statisti-
cal power to show a 50% reduction in adverse clinical 
events over 2 years in a theoretical randomized, place-
bo-controlled clinical trial of an investigational drug for 
PSC would require enrollment of at least 750 children, 
approximately every newly diagnosed child in North 
America for 3 to 4 consecutive years. Due to obvious 
cost and logistical concerns, such a study is impossible. 
The validation of biomarkers as surrogate endpoints is 
needed, but presently there is no surrogate endpoint 
that reliably predicts clinical outcomes in PSC.
Ursodeoxycholic acid (UDCA) therapy has been 
studied extensively in adult patients with PSC and 
has not been shown to improve rates of cirrhosis, liver 
transplantation, or death across a range of doses.(5-9) 
High-dose UDCA (25-30 mg/kg/day) in particular 
was found to be harmful,(8) especially for patients with 
early-stage disease.(10) The American Association for 
the Study of Liver Diseases practice guideline for PSC 
currently discourages the use of UDCA in adults.(11) 
There is a paucity of data in the literature to make 
recommendations in pediatrics, and UDCA continues 
to be administered in at least 80% of pediatric PSC 
cases.(2,12) Data from pediatric PSC case series have 
shown that treatment with UDCA improves liver bio-
chemistries and cholestatic parameters(13,14); however, 
the impact of UDCA on long-term clinical outcomes 
has not been studied.
Adult studies show that serum alkaline phosphatase 
(ALP) is of prognostic importance in PSC.(15,16) The 
incidence of clinically important endpoints such as 
development of liver cirrhosis and cholangiocarcinoma 
has been found to be higher in PSC patients with per-
sistently elevated serum ALP levels compared with 
those who achieve normalization of serum ALP.(15-17) 
Because the serum ALP levels widely fluctuate in chil-
dren due to bone growth, serum gamma glutamyltrans-
ferase (GGT) is used commonly in children as a marker 
for cholestasis.(18) Serum GGT levels have been found 
to be of prognostic importance in other pediatric 
cholestatic diseases, including biliary atresia,(19) total 
parenteral nutrition-related cholestasis,(20) idiopathic 
neonatal hepatitis,(21,22) and neonatal sepsis-related 
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cholestasis.(23) Elevated serum GGT is the most con-
sistent biochemical abnormality in pediatric patients 
with PSC, and it appears to be a more sensitive indi-
cator for bile duct injury in PSC compared with ALP 
and bilirubin.(24-31) GGT at diagnosis of PSC in chil-
dren correlates with long-term outcomes, but ALP 
does not.(2) GGT response in adult PSC patients 
paralleled other markers including ALP in a clinical 
trial of norursodeoxycholic acid.(32) Larger eleva-
tions in GGT have been associated with more exten-
sive liver fibrosis in adults with PSC.(33) The aim of 
this study was to compare biochemical responses (using 
GGT as a biomarker) with long-term outcomes, in 
response to UDCA therapy in the largest cohort of 
children with PSC worldwide.
Methods
We retrospectively reviewed medical records on all 
known PSC patients with disease onset prior to 18 
years of age at 36 different institutions throughout 
Europe, North America, the Middle East, and Asia,(2) 
including 11 non-transplant referral centers, 13 large, 
tertiary referral liver transplant centers, and 12 centers 
with population-based data (capturing all patients in a 
defined geographic region). For each patient, we col-
lected basic demographics and laboratory data at liver 
disease diagnosis (including complete blood counts, 
serum chemistries, coagulation, serum globulins, and 
autoantibody titers). Midway through enrolling new 
centers for this project, we began additionally collecting 
laboratory studies at 1 year. These data were requested 
and available from a subset of the last 17 centers submit-
ting data, which are noted in Appendix I. We included 
laboratory data present within ±6 weeks of the date 1 
year after PSC diagnosis. Because of the wide range 
of normal ALP values in children at  different ages 
due to bone turnover and growth, we normalized all 
values for age using Mayo Medical Laboratories ref-
erence values.(34) We collected the presence and type 
of associated inflammatory bowel disease (IBD), the 
presence of AIH, large-duct versus small-duct PSC 
phenotype, and the use of UDCA. UDCA was started 
within 1 month of PSC diagnosis. We observed that 
all cases of ulcerative colitis refractory to oral aminosa-
licylate monotherapy, all cases of Crohn’s disease, and 
all cases of AIH received systemic immunosuppres-
sion. Physicians generally followed established practice 
guidelines for these diseases.(35-37) Patients with PSC 
generally did not receive immunosuppression outside 
of that used for coexisting IBD or AIH. Individual 
therapeutic regimens were not recorded, however. Data 
were abstracted and de-identified at local study sites 
and reviewed and stored centrally.
The diagnosis of PSC was based on a cholestatic 
biochemical profile with either cholangiography show-
ing multifocal stricturing and segmental dilations of 
the biliary tree or liver histopathology showing peri-
ductal, concentric fibrosis, fibro-obliterative cholangi-
tis, or primary ductular involvement.(11) Patients with 
abnormal cholangiograms were labeled as large-duct 
PSC. Patients with normal cholangiograms but with 
liver biopsy consistent with PSC were labeled as small-
duct PSC. AIH was diagnosed in patients who met 
the simplified AIH criteria that have been validated 
in children,(38) based on histopathology, positive auto-
antibodies, elevated serum globulins, and exclusion of 
viral hepatitis. All patients with a “probable” or “defi-
nite” score were labeled with AIH.
We created a retrospective cohort of all patients 
and followed them from date of PSC diagnosis to the 
date of several clinical endpoints: (1) the development 
of portal hypertensive complications (ascites, hepatic 
encephalopathy, or esophageal varices with or without 
bleeding); (2) biliary complications (a clinical picture 
of biliary obstruction as evidenced by a biliary stricture 
requiring an intervention in the form of endoscopic or 
percutaneous stenting, balloon dilation, or drainage); 
(3) cholangiocarcinoma; (4) liver transplantation; or 
(5) death from liver disease. A composite outcome of 
any of these criteria was termed “event-free survival.” 
Patients were censored at the date of last known fol-
low-up. We excluded patients who presented with 
portal hypertensive or biliary complications within 3 
months of PSC diagnosis from this analysis, as their 
baseline laboratory studies were likely reflective of the 
outcomes of interest already being present. We used 
the Kaplan-Meier method to calculate annual outcome 
probabilities. The log-rank test assessed survival differ-
ences between groups.
To assess whether improvement in GGT (absolute 
level less than 50 U/L at 1 year) was associated with 
lower rates of long-term adverse outcomes, we catego-
rized patients into four groups: (1) no treatment, GGT 
at 1 year normalized; (2) UDCA treatment, GGT at 1 
year normalized; (3) no treatment, GGT at 1 year not 
normalized; and (4) UDCA treatment, GGT at 1 year 
not normalized. We excluded patients who had a GGT 
< 50 at diagnosis. We performed survival analysis strat-
ified by these groupings. We used previously identified 
risk cutoffs based on GGT and AST-to-platelet-ratio 
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Index (APRI) at PSC diagnosis to compare response 
to UDCA in patients who were low-risk (GGT < 309, 
APRI < 1.33) versus high-risk (GGT ≥ 309, APRI ≥ 
1.33)(2) of experiencing adverse clinical outcomes. We 
assessed GGT improvement over 1 year among these 
risk groupings. To assess whether UDCA treatment 
was effective for PSC phenotypes with IBD (versus 
none), AIH (versus none), or large duct disease (versus 
small), we repeated all calculations across these indi-
vidual subgroups. Appendix II details which patients 
were included for each analysis. We used Stata version 
13 (StataCorp, College Station, TX). All research was 
approved by the institutional review board of each par-
ticipating center.
Results
A total of 287 patients had adequate data for anal-
ysis. The resulting cohort was 40% female, aged 11.4 
years at PSC diagnosis, with PSC + AIH overlap pres-
ent in 39%, IBD present in 84% (ulcerative colitis in 
85% of cases and Crohn’s disease in 15%), and large 
duct involvement in 74%. UDCA therapy was used in 
81% at a mean dose of 16.5 mg/kg/day.
UDCA-treated patients were younger and had 
higher APRI values than untreated patients but were 
otherwise similar at PSC diagnosis (Table 1). After 
1 year of UDCA therapy, UDCA-treated patients 
had larger reductions in, and lower mean levels of 
taBle 1. DemogRapHiCs, BioCHemiCal Response, anD CliniCal outComes oF tReateD anD 
untReateD patients
No Treatment
(n = 51)
UDCA
(n = 236) P Value
Demographics
Age at PSC diagnosis 12.6 11.1 0.026
Inflammatory bowel disease 84% 84% 0.941
Ulcerative colitis phenotype 88% 84% 0.479
Crohn’s disease phenotype 12% 16% 0.479
Autoimmune hepatitis overlap 45% 38% 0.327
Large duct involvement 69% 75% 0.383
Laboratory studies at PSC diagnosis
GGT (U/L) 290 269 0.948
ALP (x ULN) 1.2 1.3 0.583
ALT (U/L) 175 238 0.162
APRI 0.6 1.1 0.014
Total bilirubin (mg/dL) 0.5 0.6 0.795
Laboratory studies at 1 year
GGT (U/L) 115 43 < 0.001
ALP (x ULN) 0.8 0.6 0.017
ALT (U/L) 96 62 0.003
APRI 0.5 0.4 0.031
Total bilirubin (mg/dL) 0.5 0.6 0.235
Percentage decrease in laboratory studies from diagnosis to 1 year
GGT (U/L) 60% 75% 0.002
ALP (x ULN) 12% 44% < 0.001
ALT (U/L) 22% 73% < 0.001
APRI 22% 58% < 0.001
Total bilirubin (mg/dL) 0% 9% 0.322
Rate of liver outcomes within 5 years of diagnosis
Portal hypertensive complications 18% 19% 0.814
Biliary stricture requiring procedural intervention 8% 6% 0.698
Liver transplantation 12% 11% 0.807
Cholangiocarcinoma 0% 1% 0.511
Death 0% 1% 0.511
Any adverse outcome 25% 25% 0.945
Abbreviation: ULN, upper limit of normal.
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GGT, ALT and APRI, compared with untreated 
patients. Rates of adverse liver outcomes were simi-
lar in treated and untreated groups (Fig. 1). Because 
median APRI was the only parameter that was dif-
ferent between treatment groups at baseline, we 
analyzed outcomes on and off treatment by patients 
in high and low APRI risk groups in Appendix III. 
Subgroup analyses for outcomes of UDCA therapy 
in patients with or without IBD or AIH, or with 
small-duct versus large-duct disease are detailed in 
Table 2. Patients had similar outcomes regardless of 
phenotype.
Overall, patients who showed normalization of 
GGT over 1 year fared well, and patients who did not 
fared poorly, regardless of UDCA treatment status 
(Fig. 2). Normal GGT at 1 year was present in 53% 
(112 of 210) versus 29% (14 of 48) of UDCA-treated 
versus untreated patients, respectively. Ignoring treat-
ment status and pooling treated and untreated patients 
together, patients with 1-year GGT < 50 had a 5-year 
event-free survival of 91% compared with 67% in 
patients with 1-year GGT ≥ 50 (P < 0.0001) (Fig. 3). 
A breakdown of specific events that occurred in each 
group is included in Appendix IV. Outcomes were 
best in patients who achieved the most dramatic GGT 
reductions over 1 year: 5-year event-free survival of 
88% versus 78%, versus 61% in patients who achieved a 
1-year GGT reduction (compared with GGT at diag-
nosis) of ≥ 75%, versus 26%-74% versus ≤ 25%, respec-
tively (Fig. 4).
Analysis of biochemical response in patients strat-
ified by baseline risk groups showed that most of the 
improvement in GGT observed in UDCA compared 
with no treatment arose in low-risk patients who were 
unlikely to experience adverse outcomes anyway. In 
contrast, in patients at high baseline risk of adverse out-
comes, UDCA-treated and UDCA-untreated patients 
showed a similar decline in GGT over 1 year (Table 3).
Fig. 1. Event-free survival based on UDCA treatment status.
logrank p=NS
0.5
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0.7
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years since diagnosis of PSC
no treatment
UDCA
taBle 2. CliniCal outComes in uDCa-tReateD patients BaseD on pHenotype
Portal Hypertensive Complications
(5 Years)
Biliary Complications
(5 Years)
Survival With Native Liver
(5 Years)
Event-Free Survival
(5 Years)
PSC without IBD 30%
(95% CI 15-33)
10%
(95% CI 3-29)
81%
(95% CI 48-94)
66%
(95% CI 41-82)
PSC-IBD 20%
(95% CI 14-27)
6%
(95% CI 3-11)
89%
(95% CI 81-93)
80%
(95% CI 72-85)
P value 0.460 0.541 0.849 0.186
PSC without AIH 24%
(95% CI 17-33)
8%
(95% CI 4-15)
85%
(95% CI 74-91)
74%
(95% CI 64-81)
PSC + AIH 16%
(95% CI 9-28)
4%
(95% CI 1-12)
94%
(95% CI 84-98)
84%
(95% CI 72-91)
P value 0.203 0.348 0.175 0.074
Small-duct PSC 19%
(95% CI 10-34)
0%
(95% CI 0-0)
85%
(95% CI 65-94)
82%
(95% CI 65-91)
Large-duct PSC 22%
(95% CI 16-30)
8%
(95% CI 5-15)
89%
(95% CI 80-94)
76%
(95% CI 67-83)
P value 0.933 * 0.788 0.235
*By definition, patients with small-duct PSC could not have cholangiographic abnormalities, so a statistical comparison is not listed.
Abbreviation: CI, confidence interval.
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Discussion
We assessed the biochemical and clinical response 
to UDCA therapy in the largest cohort of children 
with PSC ever reported in the literature. Regardless of 
UDCA treatment status, when a child with PSC had 
a normalized or dramatically reduced GGT at 1 year, 
outcomes were favorable, suggesting that GGT reduc-
tion may be a suitable surrogate endpoint for future 
clinical trials in children. We showed that UDCA 
therapy resulted in a larger reduction in liver biochem-
istry tests compared with no therapy, but that long-
term adverse liver outcomes were similar in treated and 
untreated patients. This was true across a range of out-
come metrics and across PSC phenotypes.
The relationship between biochemical response 
to UDCA and long-term liver outcomes seems par-
adoxical: (1) UDCA-treated patients had lower liver 
biochemistry levels on average compared with patients 
who were not treated; (2) lower liver biochemistry lev-
els generally predicted a more favorable outcome; but 
(3) UDCA treatment did not result in improved out-
comes compared with untreated patients. Analogous 
results have been seen in clinical trials involving adult 
patients: Lower or normal ALP levels were associ-
ated with improved outcomes,(15,16,39,40) regardless of 
whether UDCA was used or if the labs normalized 
without therapy.(16,17)
These seemingly discordant effects may be explained 
by several observations. Although the overall mean per-
centage GGT reduction was statistically superior in 
UDCA-treated compared with untreated patients (75% 
versus 60%), it was not clinically superior, as both groups 
showed a large reduction. The difference in GGT reduc-
tion is further clarified when patients are stratified by 
baseline risk group. GGT reduction on UDCA therapy 
was superior to no treatment only in patients at low base-
line risk of progressive liver disease, who had lower lev-
els of ductular inflammation (lower baseline GGT), and 
lower levels of hepatic fibrosis (lower baseline APRI), and 
who were unlikely to experience clinical events regard-
less. Conversely, in the highest-risk patients, with greater 
degrees of ductular inflammation (higher baseline GGT) 
and more extensive hepatic fibrosis (higher baseline 
APRI), most at risk for adverse clinical events and most 
Fig. 2. Event-free survival based on percentage reduction in 
GGT over first year after diagnosis of PSC.
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Fig. 3. Event-free survival based on normalization of GGT by 1 
year after diagnosis of PSC.
GGT at 1yr
 < 50 IU/L
GGT at 1yr
 ≥ 50 IU/L
logrank p < 0.0001
0.6
0.7
0.8
0.9
1.0
pr
op
or
tio
n 
su
rv
ivi
ng
126 120 103 90 79 69 61GGT ≥ 50
132 123 101 85 71 55 39GGT < 50
Number at risk
0 1 2 3 4 5 6
years since diagnosis of PSC
Fig. 4. Event-free survival based on UDCA treatment status and 
GGT at 1 year.
*
**
*  vs. **
 vs. 
* or **  vs.   or 
p=NS
p=NS
p<0.0010.4
0.5
0.6
0.7
0.8
0.9
1.0
pr
op
or
tio
n 
su
rv
ivi
ng
98 92 78 67 57 441yr GGT ≥ 50, UDCA
34 31 23 18 14 111yr GGT ≥ 50, No Rx
112 106 94 82 75 661yr GGT < 50, UDCA
14 14 9 8 4 31yr GGT < 50, No Rx
Number at risk
0 1 2 3 4 5
years since diagnosis of PSC
1yr GGT < 50, No Rx
1yr GGT < 50, UDCA
1yr GGT ≥ 50, No Rx
1yr GGT ≥ 50, UDCA
Hepatology CommuniCations, Vol. 2, no. 11, 2018 Deneau et al.
1375
in need of effective therapy, GGT reduction was similar 
in the treated and untreated groups.
The biochemical changes observed in untreated 
patients show that most patients undergo a spontaneous 
reduction in various parameters of hepatobiliary inflam-
mation in the year following diagnosis. We speculate that 
PSC in children may generally be detected at an earlier, 
waxing and waning inflammatory stage at the transi-
tion of prediagnostic, subclinical inflammation when 
enzymes are normal, and the chronic, unrelenting inflam-
mation and extensive biliary changes most characteristic 
of adults of PSC. ALP is known to wax and wane over 
years in PSC,(3) and it is likely that the natural history of 
GGT is similar. A regression to the mean phenomenon 
likely clouds the role of UDCA in enzymatic improve-
ment. Clinicians who follow a patient’s liver enzymes 
over time are biased to perform diagnostic testing when 
the enzymes spike upward. A subsequent reduction in 
enzymes is likely spontaneous in at least some patients 
and may be attributable to the natural history of the 
disease rather than to a treatment effect. UDCA treat-
ment may have reduced hepatobiliary inflammation and 
normalized GGT in a subset of patients who otherwise 
would not have done so on their own, but this effect is 
likely too small to be of clinical benefit, as it could not 
be detected in this cohort of hundreds of children with 
PSC.
The strength of this study was its large size and 
inclusion of patients from a diverse mix of centers. 
Patients were drawn from tertiary care referral centers, 
population-based cohorts, and small single centers, 
eliminating a referral bias. There are weaknesses to this 
study. The retrospective design prevented a standard-
ized diagnostic and therapeutic algorithm. We did not 
have data on compliance with prescribed UDCA, which 
may have been poor especially in teenage patients.
The present data show convincingly that when GGT 
is lower, patients do better. Prospective data are needed 
to validate GGT as a proven surrogate endpoint in PSC, 
but such a study could take a decade or more. Patients 
are in dire need of clinical trials to identify an effective 
therapy. The U.S. Food and Drug Administration (FDA) 
recognizes the need for surrogate endpoints for clinical 
trials in slowly progressive diseases like PSC. In situations 
in which there is insufficient prospective data to validate 
a surrogate, but where there is convincing rationale from 
epidemiologic studies such as this one, they define a sur-
rogate endpoint as “reasonably likely.”(41) Clinical trials 
may progress on the basis of reasonably likely surrogate 
endpoints in the FDA’s Accelerate Approval program, 
with future prospective validation taking place after drug 
approval.(42) We believe that the present data support 
GGT as a reasonably likely surrogate endpoint, at least 
for phase II clinical trials in children.
Conclusions
A GGT < 50 and/or GGT reduction of > 75% by 1 
year after PSC diagnosis predicts favorable 5-year out-
comes in children, regardless of whether UDCA treat-
ment is used. GGT is a useful biomarker in PSC and is 
clearly correlated with clinical liver outcomes. Phase II 
trials could proceed in children if the trials are designed 
around sustained GGT normalization as a reasonably 
likely surrogate endpoint, but prospective studies over 
several years are ultimately needed to prove the rela-
tionship between GGT response and clinical outcome.
Author Contributions: All authors participated in all 
phases of the study design, data collection, data analy-
sis, and manuscript preparation and review.
taBle 3. peRCentage ggt ReDuCtion in 1 yeaR, stRatiFieD By Baseline RisK oF CliniCal 
liVeR CompliCations
Risk Group
No Treatment
(n = 51)
UDCA
(n = 236) P Value
Based on GGT at diagnosis
Low risk (< 309 IU/L) 38% reduction
n = 37
64% reduction
n = 148
0.003
High risk (≥ 309 IU/L) 85% reduction 90% reduction 0.443
n = 14 n = 88
Based on APRI at diagnosis
Low risk (< 1.33) 60% reduction
n =38
75% reduction
n = 143
0.007
High risk (≥ 1.33) 73% reduction
n = 13
78% reduction
n = 93
0.199
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FloW DiagRam Detailing patient inClusion anD eXClusion in 
eaCH analysis
peDiatRiC psC ConsoRtium 
CenteRs paRtiCipating in tHe 
1-yeaR ggt Data analysis (in 
alpHaBetiCal oRDeR)
1.  Children’s National Medical Center, Washington, 
DC
2. Emory University, Atlanta, GA
3. Medical College of Wisconsin, Milwaukee, WI
4. Palacky University, Olomouc, Czech Republic
5. Sapienza University of Rome, Rome, Italy
6. Tel-Aviv University, Tel-Aviv, Israel
7. Texas Children’s Hospital, Houston, TX
8. University of Athens, Athens, Greece
9. University of Colorado, Aurora, CO
10. University of Helsinki, Helsinki, Finland
11.  University of Naples Federico II, Naples, Italy
12.  University of Manitoba, Winnipeg, Manitoba, 
Canada
13.  University of Pittsburgh Medical Center, 
 Pittsburgh, PA
14. University of Rochester, Rochester, NY
15.  University of Toronto, Toronto, Ontario, 
Canada
16. University of Utah, Salt Lake City, UT
17. Yale University, New Haven, CT
Fig. 5. Flow diagram detailing patient inclusion and exclusion in each analysis.
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outComes oF uDCa 
tReatment VeRsus no 
tReatment, stRatiFieD By apRi
Because the median APRI at diagnosis of PSC was 
different  between treated versus untreated patients 
(1.1 versus 0.6, P = 0.014), we performed a survival 
analysis from diagnosis of PSC to any liver event, 
stratified by patients in the highest tertile of APRI 
(≥ 1.33) and lowest two tertiles of APRI (< 1.33). 
Clinical outcomes remained similar in treated and 
 untreated patients in both the low-risk and high-risk 
APRI groups (Fig. 6).
CliniCal eVents in patients 
WitH ggt ≥ 50 VeRsus < 50 at 1 yeaR
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